The Technology
The ability to monitor low levels of biological molecules (biomarkers) in samples has great implications for diagnostics, therapeutics, and research. Currently, ELISA (enzyme-linked immunosorbent assay) and ECLIA (Electrochemiluminescence immunoassay) are the most abundant quantitative platform for biomarker detection, however, for running single-samples they are expensive and complex, with little flexibility for multiplexing (simultaneous detection of multiple biomarkers). A Point-of-Care diagnostics named CIBSI (Computational Imaging of Bead-based Sandwich Immunoassay) was developed for fast and simple biomarkers monitoring. The technology is based on computational microscopy in combination with advanced microfluidics and reduces system complexity and allowing biomarker multiplexing.
Advantages
-
Simple and fast sample preparation
-
Very rapid, high throughput detection method
-
Flexibility in terms of sample and multiplexing
Applications and Opportunities
-
Detection and quantitative measurements of biomolecules for oncology, infectious disease, neurology, inflammatory and epidemiology
-
Example application that is currently developed: early diagnostics of Cytokine Release Syndrome (CRS) in cancer patients undergoing biological treatment such as CAR-T cell therapy.
Business Development Contacts